Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields -
Analysts from UBS, Truist, BTIG, and Barclays updated ratings and price targets for Medtronic (MDT), Smith & Nephew (SNN), and GSK (GSK). MDT reported strong Q1 results and raised FY27 EPS guidance. SNN cut FY26 sales guidance. GSK plans a Phase 3 trial for its mRNA flu vaccine.
How this was made
The 30-second read
Why it matters
Provides a concise view of analyst sentiment and recent corporate developments, but adds little new primary information.
Market read
Analyst rating updates and dividend yields may influence income‑oriented investors, but no fresh material news.
What to watch
Potential regulatory or reimbursement risks for the mRNA flu vaccine.
Background
The article aggregates recent analyst rating changes and dividend yields for three health‑care companies.
Ticker impact
Analyst UBS raised price target to $110 and Truist raised to $99 after Medtronic's better‑than‑expected Q1 results and FY27 EPS guidance raise.
Potential modest price appreciation if market digests guidance lift.
Target hikes reflect improved earnings outlook but are not a primary catalyst.
Analyst BTIG initiated coverage with Neutral rating and Barclays downgraded after Smith & Nephew cut FY26 sales guidance.
Limited move expected; possible slight decline.
Guidance cut is the primary driver; analyst actions reinforce it.
Barclays downgraded and Jefferies upgraded GSK; company announced upcoming Phase 3 mRNA flu vaccine trial.
Potential upside if trial progress is viewed favorably.
Phase 3 trial launch is a forward‑looking catalyst, but analyst ratings are contradictory.
Market effects
High‑dividend health‑care stocks may attract income‑focused investors.
U.S. health‑care sector sentiment modestly affected.
Limited; primarily U.S. equity market.
Counterpoint
Income focus may be overrated if earnings growth stalls.
Key entities
- companyMedtronic PLC
Medical device manufacturer
- companySmith & Nephew PLC
Medical technology firm
- companyGSK plc
Pharmaceutical giant
